Related references
Note: Only part of the references are listed.Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
C.-H. Koehne et al.
ANNALS OF ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first- line treatment of metastatic colorectal cancer: Updated results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer
Kyriakos Zafirellis et al.
JOURNAL OF SURGICAL RESEARCH (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
Discovery of vascular permeability factor (VPF)
HF Dvorak
EXPERIMENTAL CELL RESEARCH (2006)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration
L Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations
JA Nagy et al.
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY (2002)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
